Keros Therapeutics, Inc. (NASDAQ:KROS) filed a Form 8-K with the Securities and Exchange Commission on March 09, 2026, disclosing a material event.
Keros Therapeutics, Inc.'s stock currently trades at $11.35 with a market capitalization of $878.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Keros Therapeutics, Inc.'s stock.
All SEC filings for Keros Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.